Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.05 - $40.28
Previous CloseN/A
Volume41.90K
Average Volume (3M)744.05K
Market Cap
$1.99B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)32.1
Beta0.57
Next Earnings
Aug 05, 2025EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding55,989,624
10 Day Avg. Volume759,180
30 Day Avg. Volume744,051
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$41.00Price Target Upside15.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe price target for Supernus Pharmaceuticals has been raised from $44.00 to $45.00, indicating a positive outlook.
Market OpportunityThe FDA has approved Onapgo (SC apomorphine pump) to treat OFF episodes in Parkinson's disease.
Product GrowthQelbree's launch is progressing well, with sales reaching $74.4MM and a consensus beat of ~$10MM.
Bears Say
Clinical TrialsDisappointing Phase 2b data from SPN-820 in treatment-resistant patients led to a downgrade of the stock rating.
Market SentimentDowngrading SUPN to Neutral following disappointing Phase 2b data from SPN-820.
Pipeline ChallengesThe trial for SPN-820 is on 'pause' as the company continues to analyze more data from the study.
Supernus Pharmaceuticals News
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $27.05 and its highest was $40.28 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $1.99B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Aug 05, 2025 which is in 2 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on May 06, 2025. The company reported $0.438 earnings per share for the quarter, beating the consensus estimate of $0.373 by $0.065.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.47.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 55,989,624 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.438 in its last earnings report, beating expectations of $0.373. Following the earnings report the stock price went down -4.595%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
Supernus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.00 (15.49% Upside)
$41.00 (15.49% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 402.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.4%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.07%
12-Months-Change
Fundamentals
Return on Equity
6.32%
Trailing 12-Months
Asset Growth
3.31%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. (SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company's core products include treatments for neurological disorders such as epilepsy and migraines. Supernus leverages its proprietary technology platforms and expertise in drug formulation to enhance the therapeutic benefits of its products, aiming to improve the lives of patients with CNS conditions.
SUPN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Supernus Pharmaceuticals demonstrated strong growth in core products Qelbree and GOCOVRI, introduced a promising new product ONAPGO, and maintained a solid cash position. However, these positives were offset by significant declines in legacy products and an increased operating loss, resulting in an overall net loss for the quarter.Read More>SUPN Stock 12 Month Forecast
Average Price Target
$41.00
▲(15.49%Upside)
Technical Analysis
Dynavax
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Amneal Pharmaceuticals
―
Ownership Overview
4.11% Insiders
35.15% Mutual Funds
0.23% Other Institutional Investors
31.48% Public Companies and
Individual Investors